Kendle Acquires Clinical Service Business

(Wilmington, MA, USA). The agreement with Charles River provided for the purchase of 100% of the stock of the Phase II-IV Clinical Services business by Kendle for approximately U.S.$215 million in cash plus a working-capital adjustment.

With this agreement, Kendle has strengthened its position in the clinical-development industry, adding therapeutic expertise, diversifying its customer base, and expanding its capacity to deliver large global trials.

A global clinical research organization and provider of phase II-IV clinical development services, Kendle International delivers innovative and robust clinical development solutions--from first-in-human studies through market launch and surveillance. The global clinical development business is focused on five regions: North America, Europe, Asia/Pacific, Latin America, and Africa. Kendle has conducted clinical trials or provided regulatory, pharmacovigilance, and validation services in 70 countries.

"Kendle and Charles River Clinical Services are a winning combination,” said
Candace Kendle, PharmD., chairman and CEO of Kendle. "Our newly combined organization offers our customers an expanded global platform and broadened therapeutic base for their drug development efforts, and positions Kendle for continued strong growth as we accelerate toward our $500 million mid-term revenue goal. We welcome Charles River Clinical Services associates to Kendle and look forward to serving our expanded customer base for years to come.”



Related Links:
Kendle International
Charles River Laboratories International